6-phenyl-1,3,5-triazine-2,4-diyldiamine

Repeated dose toxicity: oral

Administrative data

Endpoint:

sub-chronic toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: The study was performed according to OECD guideline study with GLP compliance.

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1993

Report date:

1993

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)

GLP compliance:

yes

Test material

Test material information

Constituent 1

Reference substance name:

6-phenyl-1,3,5-triazine-2,4-diyldiamine

EC Number:

202-095-6

EC Name:

6-phenyl-1,3,5-triazine-2,4-diyldiamine

Cas Number:

91-76-9

Molecular formula:

C9H9N5

IUPAC Name:

6-phenyl-1,3,5-triazine-2,4-diamine

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

The males weighed 185 to 238 g and the females weighed 145 to 192 g and were five to six week old.
environmental conditions were continuously monitored by a computerised system. Room temperature (20- 24 °C) and humidities (29 - 78 %) were included in the study report.

Administration / exposure

Route of administration:

oral: feed

Vehicle:

other: none

Details on oral exposure:

type of exposure: oral
post exposure period: none

Analytical verification of doses or concentrations:

no

Duration of treatment / exposure:

90 days

Frequency of treatment:

daily

Doses / concentrations

Doses / concentrations 1

Dose / conc.:

0 ppm

Remarks:

Dietary concentration

Doses / concentrations 2

Dose / conc.:

0.25 ppm

Remarks:

Dietary concentration

Doses / concentrations 3

Dose / conc.:

200 ppm

Remarks:

Dietary concentration

Doses / concentrations 4

Dose / conc.:

2 000 ppm

Remarks:

Dietary concentration

No. of animals per sex per dose:

10

Control animals:

yes

Details on study design:

Post-exposure period: none

Positive control:

none

Examinations

Observations and examinations performed and frequency:

Clinic signs:
All animals were examined for overt signs of toxicity, ill-health or behavioural change once daily.

Bodyweight: Individual bodyweights were recorded on day 0 and at weekly intervals therafter.

Food consumption: Food consumption was recorded for each cage group at weekly intervals.

Water consumption: Water consumption was observed daily for each cage group.

Opthalmoscopic Examination: The eyes of all control and high dose animals were examined before admistration of hte test and control diets and before termination of treatment (during 12 weeks)

Haematolgy: Haematolgy were preformed at the end of the study.

Sacrifice and pathology:

Pathology: All animals were subjected to a full external and internal examination.

Results and discussion

Results of examinations

Clinical signs:

no effects observed

Mortality:

no mortality observed

Body weight and weight changes:

effects observed, treatment-related

Description (incidence and severity):

high dose animals of either sex showed a substantially lower gain in body-weight than control during the treatment.

Food consumption and compound intake (if feeding study):

effects observed, treatment-related

Description (incidence and severity):

The food intake of high dose animals was lower than that of controls during the treatment period, although females appeard less adversely affected than males

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

no effects observed

Ophthalmological findings:

no effects observed

Description (incidence and severity):

No treatment-related ocular were detected

Haematological findings:

effects observed, treatment-related

Description (incidence and severity):

no toxicologically significants changes were detected

Clinical biochemistry findings:

no effects observed

Endocrine findings:

not examined

Urinalysis findings:

not specified

Behaviour (functional findings):

not specified

Organ weight findings including organ / body weight ratios:

effects observed, treatment-related

Description (incidence and severity):

High dose females showed a statistically significant increase in liver weight, relative to body weight, compared with controls. Absolute liver weights were also increased for these animals although statistical significants was not achieved.

Gross pathological findings:

effects observed, treatment-related

Description (incidence and severity):

several high dose animals of either sex showed pale adrenals and/or a darkened liver at terminal kill

Neuropathological findings:

not specified

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Description (incidence and severity):

Treatment related morphological changes were observed in the liver, spleen , kidneys, pancrease and adrenal glands.

Histopathological findings: neoplastic:

no effects observed

Details on results:

ACTUAL DOSE RECEIVED BY DOSE LEVEL BY SEX
- number of deaths at each dose: no deaths during the study
TOXIC RESPONSE/EFFECTS BY DOSE LEVEL:
- body weight gain: High dose animals of either sex showed a
substantially lower gain in bodyweight than control during the treatment
period.
- food / water consumption: High dose animales of either was lower than
that of controls during the treatment period, although females appeared
less adversely less advercely affected than males.
- ophthalmoscopic examination: No treatment-related ocular were detected.
- clinical chemistry: High dose animals of either sex showed a slight but
statistically significant increase in plasm alanine aminotransferase and
bilirubin levels compare with controles. Plasma sodium concentration was
also reduced in high dose males, although this was considered to be of
dubious toxicological significance in the absense of a concurrent effect on
plasma chloride. Intermediate and low dose animals showed no
treatment-ralated changes.
- haematology: No toxicologically significant change were detected.
- organ weights: High dose females showed a statistically significant
increase in liver weight, relative to body weight compared with controles.
Absolute liver weights were also increased for these animals although
statistical significance was not achieved. A possible treatment-related
increase in relative liver and adrenal weight was also identified for high
dose males. Intemediate and low dose animals showed not reatment-
related organ weight changes.
- gross pathology:
- histopathology: Treatment-related morphological changes were
observed in the liver,spleen, kidney, pancreas and adrenal glands. High
dose animals showed centrilobular hepatocyte enlargement, an increased
severity of splenic extramedullaly haemopiesis, hypertrophy and
vacuolation of adrenal zona glomerulosa cells together with associated
inflammatory cell infiltrates. An increased severity and/or incidence of
haemosiderin pigmnent accumulation was also observed in both the
kidneys and the spleen of high dose animals of either sex. At the
intermediate dose level, the sole treatment-related change was confined to
males and identified as an increase in the severity of hemosiderin pigment
accumulation in the spleen.
No treatment-related morphological changes were observed either for
intermediate dose females or for low dose animals of either sex.
- other: several high dose aimals of either sex showed pale adrenals and
/or a darkened liver at terminal kill whilst two of the females also had pale
kidneys. Intermediate and low dose animals showed no treatment- related
changes.

Effect levels

Key result

Dose descriptor:

NOAEL

Effect level:

19 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

histopathology: non-neoplastic

Target system / organ toxicity

Key result

Critical effects observed:

not specified

Lowest effective dose / conc.:

19 mg/kg bw/day (nominal)

Organ:

spleen

Any other information on results incl. tables

Histopathological findings

Summary incidence of spleen

Animals	Findings	Dose group (mg/kg/day)
		control	1,9	19	173
Male	Extramedullary haemopoiesis
	(minimal)	6	8	5	2
	(slight)	4	2	5	5
	(moderate)	0	0	0	3
	Pigment deposition
	(minimal)	1	1	0	0
	(slight)	9	6	4	0
	(moderate)	0	3	6	10
	(marked)	0	0	0	0
Female	Extramedullary haemopoiesis
	(minimal)	9	8	8	1
	(slight)	1	2	2	8
	(moderate)	0	0	0	1
	Pigment deposition
	(minimal)	0	2	0	0
	(slight)	5	3	5	0
	(moderate)	5	3	5	1
	(marked)	0	2	0	9

 

Applicant's summary and conclusion

Conclusions:

Benzoguanamine has a NOAEL of 19 mg/kg bw for the 90 days repeated dose toxicity.

Executive summary:

In the 90-day feeding study of rats at 0,1.9,19.0 and 173.0 mg/kg/day [OECD], the body weight gain was decreased in the high dose group. In the histopathological examination, centrilobular hepatocyte enlargement, an increased severity of extramedullary hemopoiesis in the spleen and hemosiderin pigment accumulation in the kidney and the spleen, hypertrophy and vacuolation of adrenal zona glomerulosa cells, and degeneration of pancreatic exocrine cells together with associated inflammatory cell infiltrates were observed in the high dose group. At the mid dose, the severity of hemosiderin pigment accumulation in the spleen was also increased moderately in males. This change in the spleen was considered not to be adverse effects because no other changes were observed at this dose level. Therefore, the NOAEL in the study was considered to be 19 mg/kg/day.